Natco Pharma Gets Court Nod to Make, Export Semaglutide for Diabetes and Obesity Markets
New Delhi: Natco Pharma has secured regulatory clearance from the High Court to manufacture semaglutide and export the drug to select international markets, marking a significant regulatory milestone for the company's expansion in the diabetes and obesity treatment segment.
As per the court order, the company is authorized to commence production of semaglutide, a widely prescribed therapy for type 2 diabetes and weight management. The approval also permits exports to certain overseas markets, although the specific destination countries were not disclosed, according to a report by Scanx.
The ruling allows Natco Pharma to enter the fast-growing global market for semaglutide, which belongs to the GLP-1 receptor agonist class of drugs. These therapies have witnessed strong global demand due to their proven efficacy in glycaemic control and sustained weight reduction.
The development strengthens Natco Pharma’s manufacturing capabilities and enhances its positioning in the chronic disease portfolio, particularly in metabolic disorders.
With export permissions in place, the company is also positioned to explore growth opportunities beyond the domestic market, subject to regulatory approvals in the respective jurisdictions, as per Scanx.
